<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506660</url>
  </required_header>
  <id_info>
    <org_study_id>2014-379</org_study_id>
    <nct_id>NCT02506660</nct_id>
  </id_info>
  <brief_title>Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy</brief_title>
  <acronym>Dex ISB</acronym>
  <official_title>Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <brief_summary>
    <textblock>
      Many patients undergoing ambulatory shoulder arthroscopy experience moderate to severe pain
      after surgery. Finding ways to minimize postoperative pain are ideal. Dexamethasone is a
      corticosteroid that is commonly used to prevent and/or treat nausea and inflammation. The
      addition of higher doses of dexamethasone to nerve blocks, which are injections of local
      anesthetics into the upper shoulder area, has been shown to prolong block duration and reduce
      pain. However, it is unclear whether the advantage of longer pain relief outweighs patient
      dissatisfaction with the prolonged feeling of a numb arm. Furthermore, recent studies have
      shown that systemic, intravenously administered dexamethasone may similarly reduce pain
      levels when compared with dexamethasone in the block. In our study, the investigators propose
      to examine the effect of low-dose IV versus block dexamethasone on interscalene block
      duration in patients undergoing shoulder arthroscopy. Most studies have used 4 mg or more.
      One study suggests that 1 mg may have the same effect as larger doses. Our aims are to
      determine whether the addition of low-dose dexamethasone to a local anesthetic in the block
      can prolong its duration, and whether there are differences in postoperative pain,
      consumption of painkillers, side effects, and satisfaction in patients who received IV or
      block dexamethasone. Patients (128 total) will be randomly assigned to either receive IV or
      block dexamethasone, and postoperative assessments (pain, painkiller use, side effects, block
      duration, satisfaction, complications) will be made via phone at 2, 3, 4 (if needed), and
      7-10 days after surgery. Results from this study will reveal whether patients prefer the
      longer-duration analgesia that may be obtained with low-dose dexamethasone in the block.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nerve Block Duration</measure>
    <time_frame>Postoperative day 2+</time_frame>
    <description>Time at which the pain relief from the block has completely worn off</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale Pain Scores</measure>
    <time_frame>Duration of stay in recovery room after surgery (average of 3 hours)</time_frame>
    <description>The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. &quot;no pain&quot;) to '10' representing the other pain extreme (e.g. &quot;pain as bad as you can imagine&quot; or &quot;worst pain imaginable&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>Postoperative day 2, postoperative day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>Postoperative day 2, postoperative day 3</time_frame>
    <description>Opioid-related symptom distress scale is calculated using responses to the symptom severity questions only.
For each symptom, severity is assessed by the question: &quot;(If yes), how severe was it usually?&quot; (In the past 24 hours) The responses to the severity questions are measured on a 5-point scale from 0-4 in ascending order as follows: Did not have symptom (0) Slight (1) Moderate (2) Severe (3) Very severe (4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Block Satisfaction</measure>
    <time_frame>Postoperative day 2, postoperative day 3</time_frame>
    <description>0-10 scale (0=not satisfied; 10=extremely satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Block-related Complications</measure>
    <time_frame>Postoperative day 7-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Participants Who Guessed the Correct Group</measure>
    <time_frame>Postoperative day 7-10</time_frame>
    <description>Patients will be asked whether they believe they were in the IV dexamethasone or intravenous dexamethasone group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Pain</condition>
  <condition>Shoulder Arthroscopy</condition>
  <arm_group>
    <arm_group_label>Intravenous dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perineural dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>Intravenous dexamethasone</arm_group_label>
    <arm_group_label>Perineural dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perineural dexamethasone</intervention_name>
    <description>Dexamethasone in nerve block</description>
    <arm_group_label>Perineural dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous dexamethasone</intervention_name>
    <arm_group_label>Intravenous dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous saline</intervention_name>
    <arm_group_label>Perineural dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perineural saline</intervention_name>
    <description>Saline in nerve block</description>
    <arm_group_label>Intravenous dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having ambulatory arthroscopic shoulder surgery under ultrasound-guided
             interscalene block (rotator cuffs, acromioplasties, stabilizations, labral repairs,
             etc.)

          -  Age 18-70 years

        Exclusion Criteria:

          -  Contraindication to interscalene block

          -  Known allergy/sensitivity to any study medications

          -  Having taken daily steroids for 10 days or longer anytime during the past year

          -  Body mass index &lt;18 or &gt;40

          -  History of uncontrolled nausea and vomiting with opioids or severe post-op nausea and
             vomiting (to prevent any need for higher doses of IV dexamethasone)

          -  Non-English speaking

          -  Revision procedures

          -  Additional procedures (e.g., removal of hardware, procedures involving other areas,
             etc.)

          -  Planned open procedures

          -  History of diabetes

          -  Arthroscopic irrigation and debridement secondary to infection

          -  Peripheral neuropathies affecting the operative extremity

          -  Having taken opiates daily for 10 days or longer immediately preceding surgery, 3
             times a week for greater than 3 months anytime in the past year, or currently taking
             for anything other than shoulder pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Kahn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <results_first_submitted>January 29, 2018</results_first_submitted>
  <results_first_submitted_qc>July 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 29, 2018</results_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Dexamethasone</title>
          <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
        </group>
        <group group_id="P2">
          <title>Perineural Dexamethasone</title>
          <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Dexamethasone</title>
          <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
        </group>
        <group group_id="B2">
          <title>Perineural Dexamethasone</title>
          <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="14.6"/>
                    <measurement group_id="B2" value="49.9" spread="13.6"/>
                    <measurement group_id="B3" value="48.3" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nerve Block Duration</title>
        <description>Time at which the pain relief from the block has completely worn off</description>
        <time_frame>Postoperative day 2+</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Dexamethasone</title>
            <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
          </group>
          <group group_id="O2">
            <title>Perineural Dexamethasone</title>
            <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
          </group>
        </group_list>
        <measure>
          <title>Nerve Block Duration</title>
          <description>Time at which the pain relief from the block has completely worn off</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="19.5" upper_limit="26"/>
                    <measurement group_id="O2" value="25.7" lower_limit="22.2" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numerical Rating Scale Pain Scores</title>
        <description>The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. &quot;no pain&quot;) to '10' representing the other pain extreme (e.g. &quot;pain as bad as you can imagine&quot; or &quot;worst pain imaginable&quot;)</description>
        <time_frame>Duration of stay in recovery room after surgery (average of 3 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Dexamethasone</title>
            <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
          </group>
          <group group_id="O2">
            <title>Perineural Dexamethasone</title>
            <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale Pain Scores</title>
          <description>The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. &quot;no pain&quot;) to '10' representing the other pain extreme (e.g. &quot;pain as bad as you can imagine&quot; or &quot;worst pain imaginable&quot;)</description>
          <units>Units on a Scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption</title>
        <time_frame>Postoperative day 2, postoperative day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Dexamethasone</title>
            <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
          </group>
          <group group_id="O2">
            <title>Perineural Dexamethasone</title>
            <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="55.7"/>
                    <measurement group_id="O2" value="67.4" spread="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postoperative day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="48.6"/>
                    <measurement group_id="O2" value="39.7" spread="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects</title>
        <description>Opioid-related symptom distress scale is calculated using responses to the symptom severity questions only.
For each symptom, severity is assessed by the question: &quot;(If yes), how severe was it usually?&quot; (In the past 24 hours) The responses to the severity questions are measured on a 5-point scale from 0-4 in ascending order as follows: Did not have symptom (0) Slight (1) Moderate (2) Severe (3) Very severe (4)</description>
        <time_frame>Postoperative day 2, postoperative day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Dexamethasone</title>
            <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
          </group>
          <group group_id="O2">
            <title>Perineural Dexamethasone</title>
            <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects</title>
          <description>Opioid-related symptom distress scale is calculated using responses to the symptom severity questions only.
For each symptom, severity is assessed by the question: &quot;(If yes), how severe was it usually?&quot; (In the past 24 hours) The responses to the severity questions are measured on a 5-point scale from 0-4 in ascending order as follows: Did not have symptom (0) Slight (1) Moderate (2) Severe (3) Very severe (4)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.5"/>
                    <measurement group_id="O2" value="0.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postoperative day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.4"/>
                    <measurement group_id="O2" value="0.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Block Satisfaction</title>
        <description>0-10 scale (0=not satisfied; 10=extremely satisfied)</description>
        <time_frame>Postoperative day 2, postoperative day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Dexamethasone</title>
            <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
          </group>
          <group group_id="O2">
            <title>Perineural Dexamethasone</title>
            <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
          </group>
        </group_list>
        <measure>
          <title>Block Satisfaction</title>
          <description>0-10 scale (0=not satisfied; 10=extremely satisfied)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="2.2"/>
                    <measurement group_id="O2" value="8.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postoperative day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="2.1"/>
                    <measurement group_id="O2" value="7.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Block-related Complications</title>
        <time_frame>Postoperative day 7-10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Dexamethasone</title>
            <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
          </group>
          <group group_id="O2">
            <title>Perineural Dexamethasone</title>
            <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
          </group>
        </group_list>
        <measure>
          <title>Block-related Complications</title>
          <units>patients with block complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Participants Who Guessed the Correct Group</title>
        <description>Patients will be asked whether they believe they were in the IV dexamethasone or intravenous dexamethasone group</description>
        <time_frame>Postoperative day 7-10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Dexamethasone</title>
            <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
          </group>
          <group group_id="O2">
            <title>Perineural Dexamethasone</title>
            <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants Who Guessed the Correct Group</title>
          <description>Patients will be asked whether they believe they were in the IV dexamethasone or intravenous dexamethasone group</description>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7" lower_limit="-16" upper_limit="2"/>
                    <measurement group_id="O2" value="3.4" lower_limit="-6.3" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Dexamethasone</title>
          <description>Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
Bupivacaine
Intravenous dexamethasone
Perineural saline: Saline in nerve block</description>
        </group>
        <group group_id="E2">
          <title>Perineural Dexamethasone</title>
          <description>Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
Bupivacaine
Perineural dexamethasone: Dexamethasone in nerve block
Intravenous saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard Kahn</name_or_title>
      <organization>Hospital of Special Surgery</organization>
      <phone>212-774-7274</phone>
      <email>KahnR@HSS.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

